Abstracts tagged "Duloxetine"

Abstract Number: 0475 • ACR Convergence 2021
Quantitative Analysis of Gender and Racial Disparities in Randomized Controlled Trials of Fibromyalgia
Rami Diab¹, Ali Malik², Mahmoud Al Rifai³ and Dennis Ang⁴, ¹Wake Forest Baptist Health/Wake Forest School of Medicine, Winston-Salem, NC, ²Wake Forest Baptist Health / Wake Forest School of Medicine, Winston-Salem, NC, ³Baylor College of Medicine, Houston, TX, ⁴Wake Forest School of Medicine, Winston-Salem, NC
Background/Purpose: Fibromyalgia is a chronic pain syndrome characterized by widespread musculoskeletal pain, mood disorders, fatigue, and cognitive and sleep disturbance. Mainstay treatments include tricyclic antidepressants,…
Abstract Number: 231 • 2019 ACR/ARP Annual Meeting
Duloxetine for Chronic Pain Management in a Tertiary Care Rheumatology Practice: How Patients Are Doing in the Real World
Rupal Shastri¹, Sonali Khandelwal ² and Najia Shakoor ², ¹Rush University, Chicago, IL, ²Rush University Medical Center, Chicago, IL
Background/Purpose: Chronic pain is a complicated issue that has received a significant amount of attention. In particular, studies suggesting the role of central sensitization in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].